Follow
PEDRO MOGOLLÓN ARROYO
PEDRO MOGOLLÓN ARROYO
Centro de Investigación del Cáncer-IBMCC (CSIC-USAL), 37007, Salamanca, Spain (2) Hospital
Verified email at usal.es
Title
Cited by
Cited by
Year
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
EM Algarín, A Díaz-Tejedor, P Mogollón, S Hernández-García, ...
Haematologica 105 (3), e116, 2020
502020
Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression
P Maiso, P Mogollón, EM Ocio, M Garayoa
Cancers 13 (11), 2542, 2021
312021
Biological background of resistance to current standards of care in multiple myeloma
P Mogollón, A Díaz-Tejedor, EM Algarín, T Paíno, M Garayoa, EM Ocio
Cells 8 (11), 1432, 2019
302019
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
S Hernández-García, L San-Segundo, L González-Méndez, LA Corchete, ...
Haematologica 102 (12), 2113, 2017
252017
Protein translation inhibition is involved in the activity of the pan-PIM kinase inhibitor PIM447 in combination with pomalidomide-dexamethasone in multiple myeloma
T Paíno, L González-Méndez, L San-Segundo, LA Corchete, ...
Cancers 12 (10), 2743, 2020
122020
Stroma-mediated resistance to S63845 and venetoclax through MCL-1 and BCL-2 expression changes induced by miR-193b-3p and miR-21-5p dysregulation in multiple myeloma
EM Algarín, D Quwaider, FJ Campos-Laborie, A Díaz-Tejedor, ...
Cells 10 (3), 559, 2021
42021
The novel c-MYC inhibitor IDP-121 exhibits strong anti-myeloma effect
P Krzeminski, L González-Méndez, LS Segundo, P Mogollón, A Diaz, ...
Cancer Research 81 (13_Supplement), 1291-1291, 2021
2021
THE INFRAEXPRESSION OF CD38 AND THE OVEREXPRESSION OF ANTIAPOPTOTIC MOLECULES AS POTENTIAL CAUSES OF DARATUMUMAB RESISTANCE IN MULTIPLE MYELOMAc
A Diaz Tejedor, L Gonzalez-Mendez, M Algarin Esperanza, ...
HAEMATOLOGICA 104, 204-205, 2019
2019
Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment
EM Algarín, A Díaz-Tejedor, P Mogollón, S Hernández-García, L Corchete, ...
Blood 132, 954, 2018
2018
MECHANISMS RESPONSIBLE FOR THE DE-REGULATION OF CEREBLON AS A CENTRAL ELEMENT IN RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA
P Mogollon, L Gonzalez-Mendez, S Hernandez-Garcia, P Krzeminski, ...
HAEMATOLOGICA 103, 84-85, 2018
2018
DEVELOPMENT OF A MODEL OF RESISTANCE TO CYTOTOXICITY DEPENDENT COMPLEMENTS MEDIATED BY ANTI-CD38 MONOCLONAL ANTIBODIES IN MULTIPLE MYELOMA
A Diaz-Tejedor, L Gonzalez-Mendez, EM Algarin, M Martin-Sanchez, ...
HAEMATOLOGICA 103, 85-85, 2018
2018
EFFECTIVENESS OF SIMULTANEOUS INHIBITION OF ANTI-APOPTOTIC PROTEINS MCL-1 (S63845) AND BCL-2 (VENETOCLAX) IN MULTIPLE MYELOMA
MA Esperanza, L San-Segundo, S Hernandez-Garcia, ...
HAEMATOLOGICA 103, 3-4, 2018
2018
CIRCULATING MICROVESCULARS OF PATIENTS WITH MULTIPLE MYELOMA INHIBIT THE CITOTOXIC FUNCTION OF NATURAL KILLER CELLS
EM Algarin, T Paino, P Anton, A Diaz Tejedor, L Corchete, ...
HAEMATOLOGICA 102, 9-10, 2017
2017
EVALUATION OF THE VIA OF MAPK AS A POTENTIAL MECHANISM OF RESISTANCE TO IMMUNOMODULATOR DRUGS (IMIDS) plus DEXAMETASONE IN MULTIPLE MYELOMA (MM)
P Mogollon, L Gonzalez Mendez, L San Segundo, EM Algarin, ...
HAEMATOLOGICA 102, 12-12, 2017
2017
THE PAN-INHIBITOR OF PIM KINASES, PIM447, POWER THE EFFECT OF POMALIDOMIDE AND DEXAMETASONE IN MULTIPLE MYELOMA
T Paino, L San Segundo, S Hernandez Garcia, L Gonzalez Mendez, ...
HAEMATOLOGICA 102, 3-4, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–15